A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2014
At a glance
- Drugs Siltuximab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Feb 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 Jun 2009 New trial record.